SMS Pharma. (SMSPHARMA)
TurnaroundFairStock Score: 21/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹361.35 |
| Market Cap | ₹3,384.12 Cr |
| P/E Ratio | 32.67 |
| ROCE | 12.19% |
| ROE | 14.61% |
| Dividend Yield | 0.11% |
| Profit Growth | 16.07% |
| Debt/Equity | 0.46 |
| Sales Growth | 6.14% |
| Promoter Holding | 68.07% |
| 52-Week Range | ₹270.1 — ₹494.4 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹83.91 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me look at SMS Pharma the way I would look at any business. The company has grown well: sales up 21.40% and profit up 35.93%. That is impressive. But my first question is always: what does the business earn on capital? Return on equity is 14.61% and ROCE is 12.19%. Those are respectable numbers, but they don't signal an economic fortress. A truly wonderful business should show a wide moat and consistently high returns; these figures are moderate, not exceptional.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer